Can iTeos and GSK solve TIGIT’s troubles?

Senior Writer, Biotech

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard.

Blocking artery plus surgery offers hope for reducing reoperations in brain hematoma patients

Injection of a substance to block an artery feeding the dura (protective sack around the brain) along with surgery to remove pooled blood reduced the

February 10, 2024

The year in opioid settlements: 5 things you need to know

This year, about $1.5 billion has landed in state and local government coffers from court settlements made with more than a dozen companies that manufactured,

December 21, 2023

Tiny Health, Astarte Medical Partner on Gut Health Program for Infants

What You Should Know: Astarte Medical, a leading pediatric clinical intelligence company, is forming a joint venture with Tiny Health,makers of gut microbiome tests for babies and

September 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.